{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:55:19Z","timestamp":1792684519737,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["814244"],"award-info":[{"award-number":["814244"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Osteoarthritis (OA) and rheumatoid arthritis (RA) are serious and painful diseases. Protease-activated receptor 2 (PAR2) is involved in the pathology of both OA and RA including roles in synovial hyperplasia, cartilage destruction, osteophyogenesis and pain. PAR2 is activated via cleavage of its N-terminus by serine proteases. In this study a competitive ELISA assay was developed targeting the 36-amino acid peptide that is cleaved and released after PAR2 activation (PRO-PAR2). Technical assay parameters including antibody specificity, intra- and inter-assay variation (CV%), linearity, accuracy, analyte stability and interference were evaluated. PRO-PAR2 release was confirmed after in vitro cleavage of PAR2 recombinant protein and treatment of human synovial explants with matriptase. Serum levels of 22 healthy individuals, 23 OA patients and 15 RA patients as well as a subset of RA patients treated with tocilizumab were evaluated. The PRO-PAR2 antibody was specific for the neo-epitope and intra-inter assay CV% were 6.4% and 5.8% respectively. In vitro cleavage and matriptase treated explants showed increased PRO-PAR2 levels compared to controls. In serum, PRO-PAR2 levels were increased in RA patients and decreased in RA patients treated with tocilizumab. In conclusion, PRO-PAR2 may be a potential biomarker for monitoring RA disease and pharmacodynamics of treatment.<\/jats:p>","DOI":"10.1038\/s41598-021-03346-0","type":"journal-article","created":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T11:13:41Z","timestamp":1639998821000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The activation fragment of PAR2 is elevated in serum from patients with rheumatoid arthritis and reduced in response to anti-IL6R treatment"],"prefix":"10.1038","volume":"11","author":[{"given":"Stefania","family":"Kalogera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Christine","family":"Bay-Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorbj\u00f8rn","family":"Gantzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Manon-Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten Asser","family":"Karsdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian S.","family":"Thudium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,20]]},"reference":[{"issue":"6","key":"3346_CR1","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1007\/s10067-006-0240-3","volume":"25","author":"PM Brooks","year":"2006","unstructured":"Brooks, P. M. The burden of musculoskeletal disease\u2014A global perspective. Clin Rheumatol. 25(6), 778\u2013781. https:\/\/doi.org\/10.1007\/s10067-006-0240-3 (2006).","journal-title":"Clin Rheumatol."},{"issue":"suppl_4","key":"3346_CR2","doi-asserted-by":"publisher","first-page":"iv34","DOI":"10.1093\/rheumatology\/kex417","volume":"57","author":"LA Deveza","year":"2018","unstructured":"Deveza, L. A. & Loeser, R. F. Is osteoarthritis one disease or a collection of many?. Rheumatology. 57(suppl_4), iv34\u2013iv42. https:\/\/doi.org\/10.1093\/rheumatology\/kex417 (2018).","journal-title":"Rheumatology."},{"key":"3346_CR3","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8293921","author":"YY Chow","year":"2020","unstructured":"Chow, Y. Y. & Chin, K. Y. The role of inflammation in the pathogenesis of osteoarthritis. Mediat. Inflamm. https:\/\/doi.org\/10.1155\/2020\/8293921 (2020).","journal-title":"Mediat. Inflamm."},{"key":"3346_CR4","unstructured":"Kelley\u2019s Textbook of Rheumatology\u20149th Edition. https:\/\/www.elsevier.com\/books\/kelleys-textbook-of-rheumatology\/9781437717389. Accessed 28 Jan 2021."},{"issue":"23","key":"3346_CR5","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1056\/NEJMra1004965","volume":"365","author":"IB McInnes","year":"2011","unstructured":"McInnes, I. B. & Schett, G. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 365(23), 2205\u20132219. https:\/\/doi.org\/10.1056\/NEJMra1004965 (2011).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"3346_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/BOR.0000000000000467","volume":"30","author":"AC Bay-Jensen","year":"2018","unstructured":"Bay-Jensen, A. C., Thudium, C. S. & Mobasheri, A. Development and use of biochemical markers in osteoarthritis: Current update. Curr. Opin. Rheumatol. 30(1), 121\u2013128. https:\/\/doi.org\/10.1097\/BOR.0000000000000467 (2018).","journal-title":"Curr. Opin. Rheumatol."},{"issue":"3","key":"3346_CR7","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1002\/jor.23738","volume":"36","author":"CW McIlwraith","year":"2018","unstructured":"McIlwraith, C. W. et al. Biomarkers for equine joint injury and osteoarthritis. J. Orthop. Res. 36(3), 823\u2013831. https:\/\/doi.org\/10.1002\/jor.23738 (2018).","journal-title":"J. Orthop. Res."},{"key":"3346_CR8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jprot.2018.04.030","volume":"190","author":"CS Thudium","year":"2019","unstructured":"Thudium, C. S., L\u00f6fvall, H., Karsdal, M. A., Bay-Jensen, A. C. & Bihlet, A. R. Protein biomarkers associated with pain mechanisms in osteoarthritis. J. Proteomics. 190, 55\u201366. https:\/\/doi.org\/10.1016\/j.jprot.2018.04.030 (2019).","journal-title":"J. Proteomics."},{"key":"3346_CR9","doi-asserted-by":"publisher","unstructured":"Cottrell, G. S., Amadesi, S., Schmidlin, F. & Bunnett, N. Protease-activated receptor 2: Activation, signalling and function. I: Biochemical Society Transactions. Vol. 31 1191\u20131197 (Portland Press Ltd, 2003). https:\/\/doi.org\/10.1042\/bst0311191","DOI":"10.1042\/bst0311191"},{"issue":"3","key":"3346_CR10","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1042\/bj3200939","volume":"320","author":"CM Belham","year":"1996","unstructured":"Belham, C. M. et al. Trypsin stimulates proteinase-activated receptor-2-dependent and -independent activation of mitogen-activated protein kinases. Biochem. J. 320(3), 939\u2013946. https:\/\/doi.org\/10.1042\/bj3200939 (1996).","journal-title":"Biochem. J."},{"issue":"7","key":"3346_CR11","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1074\/jbc.272.7.4043","volume":"272","author":"M Molino","year":"1997","unstructured":"Molino, M. et al. Interactions of mast cell tryptase with thrombin receptors and PAR-2. J. Biol. Chem. 272(7), 4043\u20134049. https:\/\/doi.org\/10.1074\/jbc.272.7.4043 (1997).","journal-title":"J. Biol. Chem."},{"issue":"2","key":"3346_CR12","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1161\/ATVBAHA.112.300474","volume":"33","author":"CJ Kuckleburg","year":"2013","unstructured":"Kuckleburg, C. J. & Newman, P. J. Neutrophil proteinase 3 acts on protease-activated receptor-2 to enhance vascular endothelial cell barrier function. Arterioscler. Thromb. Vasc. Biol. 33(2), 275\u2013284. https:\/\/doi.org\/10.1161\/ATVBAHA.112.300474 (2013).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"34","key":"3346_CR13","doi-asserted-by":"publisher","first-page":"26333","DOI":"10.1074\/jbc.M002941200","volume":"275","author":"T Takeuchi","year":"2000","unstructured":"Takeuchi, T. et al. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J. Biol. Chem. 275(34), 26333\u201326342. https:\/\/doi.org\/10.1074\/jbc.M002941200 (2000).","journal-title":"J. Biol. Chem."},{"key":"3346_CR14","doi-asserted-by":"publisher","unstructured":"Haraoui, B. Differentiating the efficacy of the tumor necrosis factor inhibitors. In Seminars in Arthritis and Rheumatism. Vol 34 7\u201311 (W.B. Saunders, 2005). https:\/\/doi.org\/10.1016\/j.semarthrit.2005.01.003","DOI":"10.1016\/j.semarthrit.2005.01.003"},{"issue":"5","key":"3346_CR15","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S1063-4584(97)80034-9","volume":"5","author":"MG Chambers","year":"1997","unstructured":"Chambers, M. G., Bayliss, M. T. & Mason, R. M. Chondrocyte cytokine and growth factor expression in murine osteoarthritis. Osteoarthr. Cartil. 5(5), 301\u2013308. https:\/\/doi.org\/10.1016\/S1063-4584(97)80034-9 (1997).","journal-title":"Osteoarthr. Cartil."},{"issue":"4","key":"3346_CR16","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S0002-9440(10)65368-0","volume":"154","author":"J Fernandes","year":"1999","unstructured":"Fernandes, J. et al. In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints. Prevention of osteoarthritis progression. Am. J. Pathol. 154(4), 1159\u20131169. https:\/\/doi.org\/10.1016\/S0002-9440(10)65368-0 (1999).","journal-title":"Am. J. Pathol."},{"issue":"6","key":"3346_CR17","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1002\/1529-0131(200106)44:6<1237::AID-ART214>3.0.CO;2-F","volume":"44","author":"JP Pelletier","year":"2001","unstructured":"Pelletier, J. P., Martel-Pelletier, J. & Abramson, S. B. Osteoarthritis, an inflammatory disease: Potential implication for the selection of new therapeutic targets. Arthritis Rheum. 44(6), 1237\u20131247. https:\/\/doi.org\/10.1002\/1529-0131(200106)44:6%3c1237::AID-ART214%3e3.0.CO;2-F (2001).","journal-title":"Arthritis Rheum."},{"issue":"12","key":"3346_CR18","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.7507\/1002-1892.201705025","volume":"31","author":"Q L\u00fc","year":"2017","unstructured":"L\u00fc, Q., Gou, Y., Tian, F. & Zhang, L. Research progress on protease-activated receptor 2 in pathogenesis of osteoarthritis. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 31(12), 1517\u20131522. https:\/\/doi.org\/10.7507\/1002-1892.201705025 (2017).","journal-title":"Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi"},{"issue":"3","key":"3346_CR19","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/art.22423","volume":"56","author":"EB Kelso","year":"2007","unstructured":"Kelso, E. B. et al. Expression and proinflammatory role of proteinase-activated receptor 2 in rheumatoid synovium: Ex vivo studies using a novel proteinase-activated receptor 2 antagonist. Arthritis Rheum. 56(3), 765\u2013771. https:\/\/doi.org\/10.1002\/art.22423 (2007).","journal-title":"Arthritis Rheum."},{"issue":"10","key":"3346_CR20","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1007\/s00296-011-2102-9","volume":"32","author":"AG Tindell","year":"2012","unstructured":"Tindell, A. G. et al. Correlation of protease-activated receptor-2 expression and synovitis in rheumatoid and osteoarthritis. Rheumatol Int. 32(10), 3077\u20133086. https:\/\/doi.org\/10.1007\/s00296-011-2102-9 (2012).","journal-title":"Rheumatol Int."},{"issue":"11","key":"3346_CR21","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1136\/ard.2010.130336","volume":"69","author":"WR Ferrell","year":"2010","unstructured":"Ferrell, W. R., Kelso, E. B., Lockhart, J. C., Plevin, R. & McInnes, I. B. Protease-activated receptor 2: A novel pathogenic pathway in a murine model of osteoarthritis. Ann Rheum Dis. 69(11), 2051\u20132054. https:\/\/doi.org\/10.1136\/ard.2010.130336 (2010).","journal-title":"Ann Rheum Dis."},{"key":"3346_CR22","doi-asserted-by":"publisher","unstructured":"Yan, S. et al. Down-regulation of protease-activated receptor 2 ameliorated osteoarthritis in rats through regulation of MAPK\/NF-\u03baB signaling pathway in vivo and in vitro. Biosci. Rep. https:\/\/doi.org\/10.1042\/BSR20192620 (2020).","DOI":"10.1042\/BSR20192620"},{"key":"3346_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208268","author":"C Huesa","year":"2015","unstructured":"Huesa, C. et al. Proteinase-activated receptor 2 modulates OA-related pain, cartilage and bone pathology. Ann. Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208268 (2015).","journal-title":"Ann. Rheum Dis."},{"issue":"7","key":"3346_CR24","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/89945","volume":"7","author":"N Vergnolle","year":"2001","unstructured":"Vergnolle, N. et al. Proteinase-activated receptor-2 and hyperalgesia: A novel pain pathway. Nat. Med. 7(7), 821\u2013826. https:\/\/doi.org\/10.1038\/89945 (2001).","journal-title":"Nat. Med."},{"key":"3346_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fendo.2018.00257","volume":"9","author":"K McCulloch","year":"2018","unstructured":"McCulloch, K. et al. Rheumatic disease: Protease-activated receptor-2 in synovial joint pathobiology. Front. Endocrinol. (Lausanne). 9, 1. https:\/\/doi.org\/10.3389\/fendo.2018.00257 (2018).","journal-title":"Front. Endocrinol. (Lausanne)."},{"issue":"10","key":"3346_CR26","doi-asserted-by":"publisher","first-page":"877","DOI":"10.2217\/bmm-2016-0374","volume":"11","author":"K Ourradi","year":"2017","unstructured":"Ourradi, K. & Sharif, M. Opportunities and challenges for the discovery and validation of proteomic biomarkers for common arthritic diseases. Biomark. Med. 11(10), 877\u2013892. https:\/\/doi.org\/10.2217\/bmm-2016-0374 (2017).","journal-title":"Biomark. Med."},{"issue":"2","key":"3346_CR27","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1042\/BJ20020706","volume":"368","author":"SJ Compton","year":"2002","unstructured":"Compton, S. J., Sandhu, S., Wijesuriya, S. J. & Hollenberg, M. D. Glycosylation of human proteinase-activated receptor-2 (hPAR2): Role in cell surface expression and signalling. Biochem. J. 368(2), 495\u2013505. https:\/\/doi.org\/10.1042\/BJ20020706 (2002).","journal-title":"Biochem. J."},{"issue":"2","key":"3346_CR28","doi-asserted-by":"publisher","first-page":"e0222685","DOI":"10.1371\/journal.pone.0222685","volume":"15","author":"B Liu","year":"2020","unstructured":"Liu, B. et al. The PAR2 signal peptide prevents premature receptor cleavage and activation. PLoS One. 15(2), e0222685. https:\/\/doi.org\/10.1371\/journal.pone.0222685 (2020).","journal-title":"PLoS One."},{"issue":"11","key":"3346_CR29","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.joca.2006.04.015","volume":"14","author":"Y Xiang","year":"2006","unstructured":"Xiang, Y. et al. Expression of proteinase-activated receptors (PAR)-2 in articular chondrocytes is modulated by IL-1\u03b2, TNF-\u03b1 and TGF-\u03b2. Osteoarthr. Cartil. 14(11), 1163\u20131173. https:\/\/doi.org\/10.1016\/j.joca.2006.04.015 (2006).","journal-title":"Osteoarthr. Cartil."},{"issue":"6","key":"3346_CR30","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1136\/annrheumdis-2011-200703","volume":"71","author":"A Crilly","year":"2012","unstructured":"Crilly, A. et al. PAR 2 expression in peripheral blood monocytes of patients with rheumatoid arthritis. Ann. Rheum Dis. 71(6), 1049\u20131054. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200703 (2012).","journal-title":"Ann. Rheum Dis."},{"issue":"9","key":"3346_CR31","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1136\/annrheumdis-2011-200869","volume":"71","author":"A Crilly","year":"2012","unstructured":"Crilly, A. et al. Immunomodulatory role of proteinase-activated receptor-2. Ann Rheum Dis. 71(9), 1559\u20131566. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200869 (2012).","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"3346_CR32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1471-4906(02)00013-3","volume":"24","author":"G Kaplanski","year":"2003","unstructured":"Kaplanski, G., Marin, V., Montero-Julian, F., Mantovani, A. & Farnarier, C. IL-6: A regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends Immunol. 24(1), 25\u201329. https:\/\/doi.org\/10.1016\/S1471-4906(02)00013-3 (2003).","journal-title":"Trends Immunol."},{"issue":"1","key":"3346_CR33","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12959-019-0194-8","volume":"17","author":"DM Heuberger","year":"2019","unstructured":"Heuberger, D. M. & Schuepbach, R. A. Protease-activated receptors (PARs): Mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases. Thromb J. 17(1), 4. https:\/\/doi.org\/10.1186\/s12959-019-0194-8 (2019).","journal-title":"Thromb J."},{"issue":"2","key":"3346_CR34","doi-asserted-by":"publisher","first-page":"175","DOI":"10.15403\/jgld-178","volume":"28","author":"S Sun","year":"2019","unstructured":"Sun, S. et al. Serological assessment of the quality of wound healing processes in crohn\u2019s disease. J. Gastrointest Liver Dis. 28(2), 175\u2013182. https:\/\/doi.org\/10.15403\/jgld-178 (2019).","journal-title":"J. Gastrointest Liver Dis."},{"issue":"2","key":"3346_CR35","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/BF01551818","volume":"3","author":"ML Gefter","year":"1977","unstructured":"Gefter, M. L., Margulies, D. H. & Scharff, M. D. A simple method for polyethylene glycol-promoted hybridization of mouse myeloma cells. Somatic Cell Genet. 3(2), 231\u2013236. https:\/\/doi.org\/10.1007\/BF01551818 (1977).","journal-title":"Somatic Cell Genet."},{"key":"3346_CR36","unstructured":"Cox, K. L., Devanarayan, V., Kriauciunas, A., Manetta, J., Montrose, C. & Sittampalam, S. Immunoassay Methods. Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22553884. Accessed 28 Jan 2021."},{"issue":"8","key":"3346_CR37","doi-asserted-by":"publisher","first-page":"547","DOI":"10.3109\/1354750X.2015.1105497","volume":"20","author":"C Kjelgaard-Petersen","year":"2015","unstructured":"Kjelgaard-Petersen, C. et al. Synovitis biomarkers: Ex vivo characterization of three biomarkers for identification of inflammatory osteoarthritis. Biomarkers 20(8), 547\u2013556. https:\/\/doi.org\/10.3109\/1354750X.2015.1105497 (2015).","journal-title":"Biomarkers"},{"issue":"2","key":"3346_CR38","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.semarthrit.2012.01.004","volume":"42","author":"MA Karsdal","year":"2012","unstructured":"Karsdal, M. A. et al. IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: Biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522). Semin. Arthritis Rheum 42(2), 131\u2013139. https:\/\/doi.org\/10.1016\/j.semarthrit.2012.01.004 (2012).","journal-title":"Semin. Arthritis Rheum"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03346-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03346-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03346-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T18:21:27Z","timestamp":1670091687000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03346-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,20]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["3346"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-03346-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,20]]},"assertion":[{"value":"26 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.H. is a full-time employee at Nordic Bioscience A\/S. A.C.B.J, S.S., T.M.J., M.A.K. and C.S.T. are full-time employees and shareholders at Nordic Bioscience A\/S. Nordic Bioscience is a privately-owned, small\u2013medium size enterprise (SME) partly focused on the development of biomarkers. S.K. is an industrial PhD student enrolled at University of Copenhagen and T.G. is a medical doctor at Gentofte hospital. None of the authors received any kind of financial benefits or other bonuses for the work described in this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24285"}}